Afleveringen
-
Next Generation Gene Therapies is developing novel gene therapies for the treatment of many rare diseases. In this podcast episode, the company's Co-Founder and Chief Operating Officer, Guang Qu, discusses how the company's dual-functional vector tech platform is being used to target many diseases.
-
Immunotherapies continue to redefine treatment for many types of cancer and one of the first immunotherapies approved and used clinically as a therapeutic is Interleukin-2, or IL-2.
Aulos Bioscience is an immuno-oncology company that has developed AU-007, a potential best-in-class IL-2, that improves on many of the other IL-2 products in development. In this episode, we discuss the promise of AU-007 with President and CEO, Aron Knickerbocker.
Link to Interleukin-2 review article can be found here: https://www.nature.com/articles/s41587-022-01390-3 -
Zijn er afleveringen die ontbreken?
-
In this podcast episode, we discuss the importance of addressing health equity for the rare disease community with Tamar Thompson, Head of Corporate Affairs at Alexion, AstraZeneca Rare Disease.
Tamar discussed her efforts to champion health policy, advocacy, equity, and awareness for rare diseases.
Link to NMOSD video mentioned in episode:
https://www.youtube.com/playlist?list=PLJQx_6LtucSB9GGeiWTycLm7wjK_LX0ZI -
In this podcast episode, we sit down with Christopher Heery, the Chief Medical Officer at Arcellx to learn about the company's pipeline and lead cell therapy, anitocabtagene autoleucel, or anito-cel, that is in development for multiple myeloma.
Multiple myeloma, like lymphoma and leukemia are types of cancer that start in your blood cells. -
In this podcast episode, Dr. James Zou, Associate Professor of Biomedical Data Science and Faculty DIrector of the AI for Health department at Stanford University, shares current use cases for AI in healthcare and oncology and discusses how we can overcome challenges with LLMs to unlock the full potential of AI.
-
In this episode, Genoplex Founder and CEO, Chris Leidli, and CTO, Shoukri Kattan, take a dive deep into their shared passion for health, wellness, and longevity, and explore how technology is revolutionizing patient access to advanced therapies.
Chris and Shoukri discuss the groundbreaking work happening at Genoplex, including how the company's Advanced Therapy Connect digital platform is transforming the way patients connect with life-changing treatments. -
Our guest for this podcast episode is Robb Richards, Corporate Director of Cell Therapy and Transplant at University of Pennsylvania, Penn Medicine. In this episode, we discuss how Penn Medicine is working to improve patient access to cellular therapies and how technology has evolved to streamline operational and clinical workflows to enhance patient experience.
-
Our guest for this episode is Balaji Gopalan, CEO and Co-Founder of MedStack where we discuss how MedStack's tech stack is enabling digital health start-ups to be healthcare data compliant.
MedStack streamlines compliance with out-of-the-box HIPAA controls and ready-to-use privacy policies, enabling the faster and more cost-effective development of digital health applications. With built-in security controls and third-party validation, MedStack is setting new standards in healthcare technology. -
Our guest for this podcast episode is Mike Kelly, President & CEO of NervGen Pharma. NervGen is a clinical-stage biotech company at the forefront of developing treatments that empower the nervous system to repair itself following damage from injury or disease.
-
In this podcast episode, your host, Chris Leidli, MS, MBA, goes beyond the ASCO 2024 headlines and puts a spotlight on the new clinical data for advanced therapies you don't want to miss.
-
In this episode, we preview the top American Society of Gene and Cell Therapy (ASGCT) 2024 annual meeting abstracts with guests Dr. Emily Walsh Martin from Tremont Therapeutics Consulting and Lynnea Olivarez, Incoming Chair of the ASGCT Communications Committee.
-
Over the years, electronic health records (EHRs) have revolutionized medical practice, digitizing patient data and streamlining care. But the current systems are not well suited to support collection of real-world data or the tracking of longitudinal outcomes across patient populations. This is particularly true for hematopoietic stem cell transplant and cellular therapies.
Our special guest, Dr. Wayne Liang is a leader in the stem cell transplant and cell therapy informatics field. Wayne is Director of Informatics Education and Outreach at Children's Healthcare of Atlanta, he is also a pediatric hematologist/oncologist at Aflac Cancer & Blood Disorders Center, and Assistant Professor of Pediatrics at Emory University. -
Our guest for this podcast episode is Simon Arkell, CEO of Ryght.
Ryght is developing the next generation of safe and secure generative AI to empower Life Science companies to ingest real-time data and make actionable knowledge directly available to discovery, clinical, and commercial teams. -
Our guest for this podcast episode is Doron Behar, MD, PhD, co-founder and CEO of Igentify, a digital health, artificial intelligence and genetic counseling company.
In this episode, Dr. Behar shares how his company has developed a medical-grade tech platform that optimizes genomic workflows and produces AI-generated personalized genetic counseling for patients. -
This episode features a preview of the American Society of Gene and Cell Therapy Annual Meeting scientific symposium on the impact of Generative AI on cell and gene therapy (CGT); best practices and real-world applications for communicators. Dr. Rory Bricker-Anthony shares insight into what attendees can expect to learn from the May 2024 session, including current tools and applications for CGT communicators.
-
Our guest in this podcast episode is Chris Dokomajilar, Founder and CEO of DealForma. DealForma’s comprehensive life science database includes meticulously researched licensing deal financial comps, up-to-date profiles, and historic company and pipeline data.
In this special spotlight episode, we take a deeper dive into the investment landscape for advanced therapies and also AI investment and partnership activity in the biopharma space. -
We often don’t get the chance to hear from survivors and patient advocates whose lives have been impacted by advanced medicines; so that makes this podcast episode special as we talk to Chris White, a cancer survivor who faced the unimaginable when diagnosed with Mucosal Melanoma in 2018—a rare and aggressive cancer which makes Chris's journey even more exceptional.
Today, Chris is not just a survivor; he's a beacon of inspiration. He has redirected his energy towards advocacy, prevention, and raising awareness of the complexities associated with Mucosal Melanoma.
Tune in to listen to Chris's extraordinary odyssey, exploring the challenges he faced throughout his treatment journey and proving that with resilience, determination, and hope, anything is possible. -
Our guest for this podcast episode is Mark Carbone, the CEO of PN Medical.
PN Medical is a leader in respiratory care and research. The company created “The Breather”, the world’s first combined respiratory muscle training device to strengthen respiratory muscles to optimize blood flow, lung function and strengthen the cardiopulmonary system. -
In part 2 of this special round table podcast series, we discuss the future trends and advances in cell therapy manufacturing and the impact of AI on the evolving cell therapy analytics space.
-
In part 1 of this special round table podcast series, we discuss the current trends and advances in cell therapy manufacturing and the impact of evolving manufacturing processes on the analytics space.
- Laat meer zien
